No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 16/50 27/50; SQUAMOUS CELL CARCINOMA 0/50 12/50 11/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/51 16/50; SQUAMOUS CELL CARCINOMA 0/50 12/51 13/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 28/40 53/60 43/49; CARCINOMA 0/50 2/40 21/60 8/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 13/40 51/59 40/50; CARCINOMA 0/50 1/40 11/59 17/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 3/40 16/60 16/48 OR CARCINOMA 0/50 0/40 0/60 2/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 10/40 11/59 14/50 OR CARCINOMA 0/50 0/40 2/59 1/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 45/50 49/50; CARCINOMA 0/50 23/50 27/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 38/51 39/50; CARCINOMA 9/50 18/51 21/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 28/40 47/60 29/48; CARCINOMA 0/50 12/40 57/60 45/48; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 11/60 13/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 20/40 40/59 34/50; CARCINOMA 1/50 12/40 55/59 46/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 6/59 2/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 17/50 13/49
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 26/51 24/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 2/40 7/60 9/46; TRANSITIONAL CELL CARCINOMA 0/50 0/40 8/60 16/46
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 1/38 2/58 8/50; TRANSITIONAL CELL CARCINOMA 0/50 0/38 1/58 4/50
|
Neoplastic Lesions
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Female |
Inhalation |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
Adenoma 0/50 1/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Male |
Inhalation |
Intestines (Large)
|
Some Evidence |
Some Evidence |
Adenoma 0/50 0/50 2/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-564
|
106-94-5 |
1-Bromopropane |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma 1/50 6/50 4/50 10/50 alveolar/bronchiolar carcinoma 0/50 7/50 5/50 4/50 alveolar/bronchiolar adenoma or carcinoma 1/50 9/50 8/50 14/50
|
Neoplastic Lesions
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Male |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Some Evidence |
Equivocal Evidence |
Malignant: 0/50 2/50 2/50 4/50
|
May Have Been Related
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Male |
Inhalation |
Pancreas Islet Cell
|
Some Evidence |
Equivocal Evidence |
Adenoma 0/50 5/50 4/50 5/50
|
May Have Been Related
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Female |
Inhalation |
Skin
|
Clear Evidence |
Equivocal Evidence |
Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 1/50 1/50 1/50 4/50
|
May Have Been Related
|
No
|
TR-564
|
106-94-5 |
1-Bromopropane |
Rats |
F344/N |
Male |
Inhalation |
Skin
|
Some Evidence |
Some Evidence |
Keratoacanthoma 0/50 3/50 6/50 6/50 keratoacanthoma or squamous cell carcinoma 1/50 4/50 6/50 8/50 keratoacanthoma, basal cell adenoma or carcinoma or squamous cell carcinoma 1/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Cortex
|
Positive |
Positive |
ADENOMA 0/50 7/50 5/48
|
Neoplastic Lesions
|
Yes
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 3/49 10/47; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/49 2/49 4/47
|
Neoplastic Lesions
|
Yes
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/41 1/40 6/45; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/41 2/40 1/45
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Female |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
BENIGN AND MALIGNANT TUMORS 0/50 11/50 38/50
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Male |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
BENIGN AND MALIGNANT TUMORS 0/45 1/42 21/48
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
BENIGN AND MALIGNANT TUMORS 1/50 21/50 32/50
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
BENIGN AND MALIGNANT TUMORS 0/50 32/50 39/49
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 11/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-206
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 8/49; SQUAMOUS CELL CARCINOMA 0/50 0/50 3/49
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 7/49 13/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/49 5/49 37/50
|
Neoplastic Lesions
|
Yes
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/41 0/48 11/46; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/41 3/48 19/46
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 1/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/48 4/47 COMBINED 0/50 0/48 5/47
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Positive |
Positive |
ADENOCARCINOMA 2/50 14/50 8/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Positive |
Positive |
FIBROADENOMA 4/50 29/50 24/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Male |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Positive |
Positive |
MESOTHELIOMA 0/50 7/50 25/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
CARCINOMA 0/50 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
ADENOMA 0/50 11/50 3/50; ADENOCARCINOMA 0/50 20/50 29/50; CARCINOMA 0/50 0/50 25/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Positive |
Positive |
ADENOMA 0/50 11/50 0/50; ADENOCARCINOMA 0/50 20/50 28/50; CARCINOMA 0/50 0/50 21/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Positive |
Positive |
FIBROSARCOMA 0/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA 0/50 11/50 23/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Female |
Inhalation |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-210
|
106-93-4 |
1,2-Dibromoethane |
Rats |
F344/N |
Male |
Inhalation |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA 0/50 1/50 15/50
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Positive |
Positive |
(POLYP, SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
(HEMANGIOSARCOMA)
|
Neoplastic Lesions
|
Yes
|
TR-329
|
106-88-7 |
1,2-Epoxybutane |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 1/50 1/49 OR ALVEOLAR/BRONCHIOLR CARCINOMA 0/50 1/50 4/49 COMBINED 0/50 2/50 5/49
|
Neoplastic Lesions
|
No
|
TR-329
|
106-88-7 |
1,2-Epoxybutane |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 7/50
|
Neoplastic Lesions
|
No
|
TR-329
|
106-88-7 |
1,2-Epoxybutane |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/50 2/48 1/49
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 4/42 10/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 5/40 0/44
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 1/50 10/49 10/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 0/50 23/50 29/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ACINAR CELL CARCINOMA 0/50 2/49 6/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/49 6/45 12/48
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 11/48 18/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 16/49 7/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 1/52 9/52; SQUAMOUS CELL CARCINOMA 0/52 0/52 4/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 2/52 3/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/52 6/52 7/52
|
Neoplastic Lesions
|
Yes
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 8/50
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL CARCINOMA 0/50 8/50 21/48
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA, ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(POLYP)
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 44/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 48/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60
|
Neoplastic Lesions
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60
|
Neoplastic Lesions
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/60 1/45 3/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/60 0/45 3/75 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
Adenoma 1/50 1/50 3/50 4/49
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Malignant Lymphoma: 2/50 5/50 8/50 7/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 1/50 1/50 1/49 3/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/50 4/50 4/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiolar adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thoracic Cavity
|
Clear Evidence |
Equivocal Evidence |
Malignant Schwannoma: 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50
|
Neoplastic Lesions
|
No
|
TR-535
|
822-36-6 |
4-Methylimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 9/50 7/50 16/50 20/50
|
Neoplastic Lesions
|
Yes
|
TR-535
|
822-36-6 |
4-Methylimidazole |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 8/50 16/50 8/50 ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 0/50 2/50 7/50 COMBINED 3/50 8/50 17/50 14/50
|
Neoplastic Lesions
|
Yes
|
TR-535
|
822-36-6 |
4-Methylimidazole |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 4/50 4/50 8/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA (COMBINED) 9/50 13/50 16/50 22/50
|
Neoplastic Lesions
|
Yes
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 5/50 8/50 6/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/50 3/50 1/50 COMBINED 4/50 9/50 11/50 7/50
|
May Have Been Related
|
No
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Mice |
B6C3F1 |
Female |
Topical Application |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN MIXED TUMORS 0/50 0/49 11/49 6/50, GRANULOSA CELL TUMOR 0/50 0/49 5/49 10/50, LUTEOMA 1/50 0/49 0/49 0/50, OR MALIGNANT GRANULOSA CELL TUMOR 0/50 0/49 2/49 2/50 COMBINED 1/50 0/49 17/49 18/50
|
Neoplastic Lesions
|
No
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 6/50 37/50 43/50
|
Neoplastic Lesions
|
No
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 14/50 40/50 43/50
|
Neoplastic Lesions
|
No
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL CARCINOMA 2/50 5/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 16/50 34/50
|
Neoplastic Lesions
|
No
|
TR-362
|
106-87-6 |
4-Vinyl-1-cyclohexene diepoxide |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL CARCINOMA 2/50 4/50 8/50; SQUAMOUS CELL CARCINOMA 0/50 33/50 36/50
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Ovary
|
Positive |
Positive |
(TUBULAR CELL ADENOMA OR GRANULOSA CELL TUMOR OR LUTEOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 11/50 8/49 OR ADENOCARCINOMA 0/50 1/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 9/50 9/49
|
May Have Been Related
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
FIBROMA 1/50 5/50 7/49
|
May Have Been Related
|
No
|
TR-359
|
298-81-7 |
8-Methoxypsoralen |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 7/50 4/49
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 1/4 6/48 12/47 3/48 8/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 4/46 0/46 2/48 5/45 8/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 0/45 8/44 20/48 32/47 31/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 2/48 1/48 0/48 2/48 4/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 1/48 2/48 3/48 4/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 1/48 3/48
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 18/48 24/46 22/47 31/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/48 2/48 1/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/50 6/50 24/50 19/50 SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 11/50 COMBINED 3/50 7/50 25/50 29/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/50 4/50 19/50 25/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 8/50 9/50 COMBINED 3/50 4/50 26/50 32/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 10/50 25/50 23/50 ADENOMA OR CARCINOMA 11/50 10/50 26/50 25/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 16/50 24/50 27/50 ADENOMA OR CARCINOMA 6/50 16/50 27/50 30/50
|
Neoplastic Lesions
|
Yes
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 6/50 6/50 14/50 9/50
|
May Have Been Related
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Ovary
|
Clear Evidence |
Equivocal Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/50 0/50 4/50 1/50
|
May Have Been Related
|
No
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Rats |
Wistar Han |
Female |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
benign pheochromocytoma (0/49, 2/49, 2/49, 6/50); benign or malignant pheochromocytoma (0/49, 2/49, 2/49, 7/50)
|
Neoplastic Lesions
|
No
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Rats |
Wistar Han |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
benign pheochromocytoma (1/49, 0/50, 2/49, 7/50)
|
Neoplastic Lesions
|
No
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Mice |
B6C3F1 |
Female |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant lymphoma (7/50, 17/50, 20/50, 27/50)
|
Neoplastic Lesions
|
Yes
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Rats |
Wistar Han |
Female |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
cystic keratinizing epithelioma or squamous cell carcinoma (0/50, 0/50, 0/50, 3/50)
|
May Have Been Related
|
Yes
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (1/50, 10/50, 19/50, 8/50); alveolar/bronchiolar carcinoma (2/50, 14/50, 11/50, 11/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 22/50, 27/50, 18/50)
|
Neoplastic Lesions
|
Yes
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar carcinoma (4/50, 18/50, 20/50, 27/50)
|
Neoplastic Lesions
|
Yes
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Rats |
Wistar Han |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar adenoma (0/50, 2/50, 6/50, 5/50)
|
Neoplastic Lesions
|
Yes
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Rats |
Wistar Han |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar adenoma (3/50, 4/50, 6/50, 8/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 4/50, 8/50, 8/50)
|
Neoplastic Lesions
|
No
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Skin
|
Clear Evidence |
Equivocal Evidence |
squamous cell carcinoma (0/50, 0/50, 0/50, 2/50)
|
May Have Been Related
|
No
|
TR-590
|
1309-64-4 |
Antimony Trioxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Skin
|
Clear Evidence |
Clear Evidence |
fibrous histiocytoma (0/50, 1/50, 1/50, 4/50); fibrous histiocytoma or fibrosarcoma (0/50, 1/50, 3/50, 4/50)
|
Neoplastic Lesions
|
No
|
TR-522
|
30516-87-1 |
AZT transplacental carcinogenesis study |
Mice |
Swiss CD-1 |
Female |
In Utero |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-522
|
30516-87-1 |
AZT transplacental carcinogenesis study |
Mice |
Swiss CD-1 |
Male |
In Utero |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 5/50 11/50 6/50 11/37 8/32 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 14/50 20/50 13/50 18/37 18/32
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 9/46 13/49 11/48
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 15/49 25/45 26/50 22/49
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/49 10/48 10/50 15/49
|
Neoplastic Lesions
|
Yes
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 2/42 5/50 9/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 3/42 6/50 6/49 COMBINED 4/49 5/42 10/50 13/49
|
Neoplastic Lesions
|
Yes
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/49 6/48 8/50 12/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 5/49 11/48 12/50 14/49 COMBINED 10/49 16/48 19/50 21/49
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/49 2/45 5/50 10/49; CARCINOSARCOMA 0/49 0/45 1/50 4/49
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 4/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 4/50 5/50 COMBINED 1/50 5/50 12/50 9/50
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 6/50 11/50 13/50 OR SQUAMOUS CELL CARCINOMA 0/50 3/50 5/50 7/50 COMBINED 1/50 9/50 16/50 19/50
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Female |
Gavage |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN MIXED TUMORS 0/47 1/44 12/49 7/48; GRANULOSA CELL TUMOR 1/47 1/44 6/49 7/48
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/21 3/28 18/29 28/35
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 1/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 5/50 3/50 8/50
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/43 0/32 1/37 3/31
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Mice |
B6C3F1 |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/43 1/34 4/40 21/39
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/45 5/40 5/44 14/46
|
Neoplastic Lesions
|
No
|
TR-289
|
71-43-2 |
Benzene |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 2/32 6/46 10/42
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 COMBINED 2/50 9/50 5/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/49 7/39 10/48 OR SQUAMOUS CELL CARCINOMA 0/49 4/39 3/48 COMBINED 2/49 11/39 13/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOCARCINOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 22/48 21/47; HEPATOBLASTOMA 0/50 1/48 2/47; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 3/50 3/48 1/47 COMBINED 4/50 25/48 22/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/49 24/39 34/48; HEPATOBLASTOMA 0/49 3/39 18/48; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 9/49 8/39 9/48 COMBINED 12/49 31/39 40/48
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 5/48 13/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/48 3/47 COMBINED 2/50 9/48 14/47
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 7/39 15/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/49 3/39 5/48 COMBINED 10/49 9/39 19/48
|
Neoplastic Lesions
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Rats |
F344/N |
Male |
Dosed-Water |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 11/49 20/50 26/50 23/50 hepatoblastoma 1/49 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma 6/50 11/50 16/50 8/50 alveolar/bronchiolar adenoma or carcinoma 14/50 19/50 21/50 15/50
|
May Have Been Related
|
Yes
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/50 6/50 4/49 11/50 carcinoma 7/50 8/50 10/49 13/50 alveolar/bronchiolar adenoma or carcinoma 11/50 13/50 13/49 21/50
|
Neoplastic Lesions
|
Yes
|
TR-580
|
108-99-6 |
beta-Picoline |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar adenoma 0/50 3/50 2/50 5/50 alveolar/bronchiolar adenoma or carcinoma 0/50 4/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/49 1/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/49 1/49 COMBINED 0/50 0/49 2/49
|
May Have Been Related
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 5/50 13/50 17/50
|
Neoplastic Lesions
|
Yes
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 4/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 13/50 11/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 8/48 23/47 17/50 21/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 2/50 0/49 COMBINED 8/48 23/47 18/50 21/49
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Brain
|
Some Evidence |
Equivocal Evidence |
GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
GLIOMA 0/50 1/50 1/48 3/50
|
Neoplastic Lesions
|
Yes
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/48 0/49 1/48 1/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/48 0/49 3/48 0/48 COMBINED 0/48 0/49 4/48 1/48
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 6/50 8/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 0/50 5/50 6/50 COMBINED 7/50 6/50 12/50 15/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 0/47 3/49
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 3/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 0/35 1/65 2/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50
|
Neoplastic Lesions
|
Yes
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50
|
May Have Been Related
|
Yes
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 3/35 6/65 3/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 9/49 10/50; CARCINOMA 9/50 17/49 20/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/50 3/49 11/50; CARCINOMA 0/50 3/49 5/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 21/50 23/50
|
Neoplastic Lesions
|
Yes
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 5/50
|
May Have Been Related
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 8/50 4/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous Cell Papilloma 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
|
May Have Been Related
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/50 4/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 24/49 32/50 36/50 36/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 4/50 8/50 3/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 11/50 11/50 18/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
benign pheochromocytoma 6/50 12/50 22/50 36/50 malignant pheochromocytoma 0/50 2/50 3/50 11/50 benign or malignant pheochromocytoma 6/50 13/50 23/50 40/50
|
Neoplastic Lesions
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Male |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
benign pheochromocytoma 15/50 23/50 37/50 34/50 malignant pheochromocytoma 2/50 2/50 9/50 16/50 benign or malignant pheochromocytoma 17/50 23/50 38/50 41/50
|
Neoplastic Lesions
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Female |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
Mononuclear Cell Leukemia 16/50 29/50 28/50 27/50
|
Neoplastic Lesions
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (standard evaluation) 0/50 1/50 0/50 4/50 (standard and extended evaluations combined) 3/50 1/50 1/50 7/50
|
May Have Been Related
|
Yes
|
TR-581
|
7440-48-4 |
Cobalt |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma 3/49 9/50 8/50 10/50 alveolar/bronchiolar carcinoma 5/49 25/50 38/50 43/50 alveolar/bronchiolar adenoma or carcinoma 8/49 30/50 41/50 45/50
|
May Have Been Related
|
Yes
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Male |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
cystic keratinizing epithelioma 0/50 1/50 0/50 1/50
|
May Have Been Related
|
Yes
|
TR-581
|
7440-48-4 |
Cobalt |
Mice |
B6C3F1/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 7/50 11/49 15/50 3/50 alveolar/bronchiolar carcinoma 11/50 38/49 42/50 46/50 alveolar/bronchiolar adenoma or carcinoma 16/50 41/49 43/50 47/50
|
Neoplastic Lesions
|
Yes
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50 7/50 9/50 13/50 alveolar/bronchiolar carcinoma 0/50 9/50 17/50 30/50 alveolar/bronchiolar adenoma or carcinoma 2/50 15/50 20/50 38/50 cystic keratinizing epithelioma 0/50 4/50 1/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50 10/50 10/50 14/50 alveolar/bronchiolar carcinoma 0/50 16/50 34/50 36/50 alveolar/bronchiolar adenoma or carcinoma 2/50 25/50 39/50 44/50
|
Neoplastic Lesions
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Female |
Inhalation |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
carcinoma 1/50 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-581
|
7440-48-4 |
Cobalt |
Rats |
F344/NTac |
Male |
Inhalation |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
adenoma or carcinoma 2/50 2/50 10/48 9/49
|
Neoplastic Lesions
|
No
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Equivocal Evidence |
BENIGN PHEOCHROMOCYTOMA 14/50 19/50 23/49 20/50, MALIGNANT PHEOCHROMOCYTOMA 0/50 2/50 2/49 2/50, OR COMPLEX PHEOCHROMOCYTOMA 1/50 0/50 1/49 0/50 COMBINED 15/50 19/50 25/49 20/50
|
May Have Been Related
|
No
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 2/48 1/49 3/50 8/48, MALIGNANT PHEOCHROMOCYTOMA 0/48 0/49 1/50 1/48 OR COMPLEX PHEOCHROMOCYTOMA 0/48 0/49 0/50 1/48 COMBINED 2/48 1/49 4/50 10/48
|
Neoplastic Lesions
|
Yes
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 6/50 9/50 10/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 1/50 4/50 9/50 COMBINED 4/50 7/50 13/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 9/50 12/50 13/50 18/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 4/50 5/50 7/50 11/50 COMBINED 11/50 14/50 19/50 28/50
|
Neoplastic Lesions
|
Yes
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 1/49 10/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 6/50 6/50 COMBINED 0/50 3/49 16/50 16/50
|
Neoplastic Lesions
|
Yes
|
TR-471
|
10026-24-1 |
Cobalt sulfate heptahydrate |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 4/50 1/48 6/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/50 3/48 1/50 COMBINED 1/50 4/50 4/48 7/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 5/50 2/51 2/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 2/50 0/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/50 0/50 2/49, STEP SECTIONS 0/49 0/50 1/50 1/49
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/49 2/50 2/51 1/50, STEP SECTIONS 0/49 4/50 5/51 4/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 26/49 29/51 12/50
|
Neoplastic Lesions
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/51 5/49 7/49 20/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 0/49 0/49 7/51 COMBINED 2/51 5/49 7/49 27/51
|
Neoplastic Lesions
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 14/50 8/50 14/50 24/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 1/50 2/50 1/51 COMBINED 14/50 9/50 15/50 25/51
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
renal tubule, adenoma or carcinoma (2/50, 5/50, 8/50, 7/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma (18/50, 23/50, 27/50, 29/50); adenoma or carcinoma (25/50, 26/50, 29/50, 36/50)
|
Neoplastic Lesions
|
Yes
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (1/50, 26/50, 36/50, 38/50); alveolar/bronchiolar carcinoma (3/50, 16/50, 20/50, 34/50); alveolar/bronchiolar adenoma or carcinoma (4/50, 31/50, 42/50, 46/50)
|
Neoplastic Lesions
|
Yes
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (13/50, 31/50, 31/50, 29/50); alveolar/bronchiolar carcinoma (9/50, 19/50, 32/50, 33/50); alveolar/bronchiolar adenoma or carcinoma (19/50, 38/50, 42/50, 43/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma (0/50, 7/50, 18/49, 10/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Some Evidence |
Some Evidence |
respiratory epithelium, adenoma (0/50, 5/48, 4/50, 3/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Spleen
|
Clear Evidence |
Equivocal Evidence |
hemangioscaroma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell adenoma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma
|
May Have Been Related
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 3/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Equivocal Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/48; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/48
|
Neoplastic Lesions
|
Yes
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/50 5/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/50 20/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Female |
Gavage |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Rats |
Sprague Dawley |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Rats |
Sprague Dawley |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
Yes
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Female |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Male |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 3/50 2/50 4/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 0/50 3/50 3/50 7/50; (SINGLE AND STEP SECTIONS) ADENOMA 3/50 5/50 7/50 20/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 3/50 5/50 8/50 21/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/50 0/50 1/49 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 0/50 1/50 8/49
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 9/50 12/50 16/50 OR CARCINOMA 7/50 4/50 3/50 12/50 COMBINED 13/50 12/50 15/50 25/50
|
Neoplastic Lesions
|
Yes
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 9/50 10/50 16/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 1/50 5/50 3/50 COMBINED 7/50 10/50 15/50 19/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Clear Evidence |
ADENOMA 36/50 33/50 40/50 44/50
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
CYSTADENOMA 1/46 6/46 8/47
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
CYSTADENOMA 1/43 9/44 8/42
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 9/49 6/48 22/49
|
Neoplastic Lesions
|
Yes
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49
|
Neoplastic Lesions
|
Yes
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49
|
Neoplastic Lesions
|
No
|
TR-326
|
75-21-8 |
Ethylene oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/49 1/47 5/49
|
Neoplastic Lesions
|
No
|
TR-492
|
1303-00-0 |
Gallium arsenide |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 4/50 5/49 6/50 13/49
|
Neoplastic Lesions
|
No
|
TR-492
|
1303-00-0 |
Gallium arsenide |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 22/50 21/50 18/50 33/50
|
Neoplastic Lesions
|
Yes
|
TR-492
|
1303-00-0 |
Gallium arsenide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/50 2/50 7/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/50 2/50 3/50 COMBINED 0/50 0/50 4/50 9/50
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
All Organs
|
Clear Evidence |
Clear Evidence |
Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 4/48 6/48 7/48 11/48 14/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/45 3/48 10/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/48 3/48 10/47 17/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/45 1/45 1/47 5/45 9/44
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/48 1/48 0/48 0/47 3/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/45 19/47 20/47 24/46 40/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 3/47 17/47 23/47 32/46 42/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant schwannoma 2/48 3/48 3/48 7/47 8/48
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 26/48 35/48 33/48 36/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Equivocal Evidence |
granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/47 3/48 6/47 13/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 24/48 47/49
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 11/50 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
NEOPLASTIC NODULE 0/49 0/50 3/50; CARCINOMA 1/49 0/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/49 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/49 4/50 COMBINED 1/50 3/49 7/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/47 0/49 5/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 2/50 6/48 2/50 9/49
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 10/50 22/50 16/49 23/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 10/50 26/50 18/49 24/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 5/50 3/50; ADEMONA OR CARCINOMA 1/50 2/50 6/50 3/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 12/50 14/50 18/50 14/50; CARCINOMA 6/50 17/50 8/50 10/50; COMBINED 18/50 28/50 24/50 23/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 24/50 23/50 32/50; CARCINOMA 11/50 22/50 23/50 16/50; COMBINED 26/50 40/50 37/50 39/50
|
Neoplastic Lesions
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 3/50 6/50 10/50 7/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/50 7/50; COMBINED 4/50 11/50 15/50 14/50
|
Neoplastic Lesions
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 15/50 22/50 13/50
|
Neoplastic Lesions
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 0/50 7/50 5/50 19/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 3/50 1/50 11/50; COMBINED 1/50 10/50 6/50 26/50
|
Neoplastic Lesions
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 6/50 13/50 27/50 30/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 10/50 8/50 16/50; COMBINED 7/50 22/50 30/50 35/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 8/50 3/50 2/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Skin
|
Clear Evidence |
Equivocal Evidence |
FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50
|
May Have Been Related
|
Yes
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/46 2/45 2/46 10/46 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/46 1/45 0/46 1/46 COMBINED 0/46 3/45 2/46 11/46
|
Neoplastic Lesions
|
Yes
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/46 3/46 12/46 13/46 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/46 2/46 1/46 6/46 COMBINED 1/46 5/46 13/46 15/46
|
Neoplastic Lesions
|
Yes
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/51 14/51 7/50 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/51 2/51 2/50 2/50 COMBINED 6/51 15/51 9/50 19/50
|
Neoplastic Lesions
|
Yes
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 12/50 13/49 17/53 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/49 4/53 COMBINED 8/50 16/50 16/49 19/53
|
Neoplastic Lesions
|
No
|
TR-448
|
542-56-3 |
Isobutyl nitrite |
Mice |
B6C3F1 |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA 1/50 0/50 0/50 5/53
|
May Have Been Related
|
Yes
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar carcinoma 4/50 1/50 4/50 8/50 alveolar/bronchiolar adenoma or carcinoma 4/50 5/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Male |
Inhalation |
Prostate Gland
|
Equivocal Evidence |
Equivocal Evidence |
adenoma 1/50 1/50 1/50 3/50 adenoma or carcinoma 1/50 1/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Female |
Inhalation |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
squamous cell papilloma or keratoacanthoma 0/50 0/50 0/50 4/50
|
May Have Been Related
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Mice |
B6C3F1/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
carcinoma 0/50 0/48 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-586
|
CIMSTAR3800 |
Metal Working Fluids: CIMSTAR 3800 |
Rats |
Wistar Han |
Female |
Inhalation |
Uterus
|
Equivocal Evidence |
Equivocal Evidence |
adenocarcinoma or mixed malignant Mullerian tumor (original and residual longitudinal evaluation combined) 1/50 4/50 5/50 6/50
|
May Have Been Related
|
No
|
TR-591
|
TRIMVX |
Metal Working Fluids: TRIM® VX |
Rats |
Wistar Han |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-591
|
TRIMVX |
Metal Working Fluids: TRIM® VX |
Rats |
Wistar Han |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
alveolar/bronchiolar carcinoma 0/50 0/50 0/50 2/50 alveolar/bronchiolar adenoma or carcinoma 0/50 0/50 0/50 3/50
|
May Have Been Related
|
Yes
|
TR-591
|
TRIMVX |
Metal Working Fluids: TRIM® VX |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar carcinoma 5/50 3/50 6/50 14/50 alveolar/bronchiolar adenoma or carcinoma 9/50 8/50 8/50 20/50
|
Neoplastic Lesions
|
Yes
|
TR-591
|
TRIMVX |
Metal Working Fluids: TRIM® VX |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma or carcinoma 14/50 14/50 11/49 23/50
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/48 22/48 OR CARCINOMA 1/50 11/48 32/48 COMBINED 3/50 16/48 40/48
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 14/49 14/49 OR CARCINOMA 13/50 15/49 26/49 COMBINED 22/50 24/49 33/49
|
Neoplastic Lesions
|
Yes
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 23/48 28/48; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 13/48 29/48
|
Neoplastic Lesions
|
Yes
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 19/50 24/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 10/50 28/50
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 5/50 11/50 13/50 22/50 COMBINED 5/50 11/50 13/50 23/50
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Rats |
F344/N |
Male |
Inhalation |
Mammary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 0/50 0/50 2/50 4/50 COMBINED 0/50 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-462
|
1313-27-5 |
Molybdenum trioxide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/50 0/50 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/50 1/50 1/50 COMBINED 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-462
|
1313-27-5 |
Molybdenum trioxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 4/50 8/49 9/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 2/50 0/49 6/50 COMBINED 3/50 6/50 8/49 15/49
|
Neoplastic Lesions
|
Yes
|
TR-462
|
1313-27-5 |
Molybdenum trioxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 9/50 14/50 10/49 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 16/50 14/49 10/50 COMBINED 11/50 27/50 21/49 18/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/47 8/45 20/48
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/48 14/49 29/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 4/50 17/49
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 4/50 19/50 OR CARCINOMA 6/50 13/50 12/50 COMBINED 12/50 17/50 26/50
|
Neoplastic Lesions
|
Yes
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 4/50 7/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 5/50 7/49 COMBINED 6/50 8/50 13/49
|
Neoplastic Lesions
|
Yes
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 6/50 11/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/49 4/50 10/50 COMBINED 5/49 10/50 18/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/50 5/45 5/47
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/50, 5/50, 6/50, 7/50; squamous cell papilloma or carcinoma 1/50, 6/50, 6/50, 7/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 19/50, 37/50, 44/50; hepatocellular carcinoma 6/50, 13/50, 18/50, 31/50; hepatoblastoma 0/50, 1/50, 0/50, 4/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma, multiple 17/50, 19/50, 27/50, 26/50; hepatocellular carcinoma 22/50, 25/50, 30/50, 36/50; hepatoblastoma 1/50, 5/50, 10/50, 8/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 0/50, 4/49; hepatocellular adenoma or carcinoma 0/50, 1/50, 1/50, 7/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 1/50, 6/50; hepatocellular adenoma or carcinoma 0/50, 0/50, 2/50, 6/50
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50, 4/50, 8/50, 12/50; alveolar/bronchiolar adenoma or carcinoma 2/50, 5/50, 9/50, 13/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 1/49, 0/50, 2/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 3/49, 2/50, 11/49; transitional epithelium, adenoma or carcinoma 0/50, 3/49, 2/50, 13/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma 1/50, 2/49, 2/50, 4/49
|
May Have Been Related
|
Yes
|
TR-410
|
91-20-3 |
Naphthalene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/68 2/64 28/134
|
Neoplastic Lesions
|
No
|
TR-451
|
1313-99-1 |
Nickel (II) oxide |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 4/51 7/52 6/53 18/53
|
Neoplastic Lesions
|
No
|
TR-451
|
1313-99-1 |
Nickel (II) oxide |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 27/54 24/52 26/53 32/52 OR MALIGNANT PHEOCHROMOCYTOMA 0/54 0/52 1/53 6/52 COMBINED 27/54 24/52 27/53 35/52
|
Neoplastic Lesions
|
No
|
TR-451
|
1313-99-1 |
Nickel (II) oxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/64 4/66 10/63 3/64 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 4/64 11/66 4/63 5/64 COMBINED 6/64 15/66 12/63 8/64
|
Neoplastic Lesions
|
Yes
|
TR-451
|
1313-99-1 |
Nickel (II) oxide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/53 0/53 1/53 4/54 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 0/53 5/53 1/54 COMBINED 1/53 0/53 6/53 5/54
|
Neoplastic Lesions
|
Yes
|
TR-451
|
1313-99-1 |
Nickel (II) oxide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/54 1/53 3/53 2/52 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/54 0/53 3/53 2/52 OR SQUAMOUS CELL CARCINOMA 1/54 0/53 0/53 0/52 COMBINED 1/54 1/53 6/53 4/52
|
Neoplastic Lesions
|
No
|
TR-453
|
12035-72-2 |
Nickel subsulfide |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 2/53 7/53 36/53
|
Neoplastic Lesions
|
No
|
TR-453
|
12035-72-2 |
Nickel subsulfide |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 13/53 30/52 38/53 OR MALIGNANT PHEOCHROMOCYTOMA 0/53 2/52 10/53 COMBINED 14/53 30/52 38/53
|
Neoplastic Lesions
|
Yes
|
TR-453
|
12035-72-2 |
Nickel subsulfide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/53 5/53 5/53 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 3/53 6/53 OR SQUAMOUS CELL CARCINOMA 0/53 1/53 0/53 COMBINED 2/53 6/53 9/53
|
Neoplastic Lesions
|
Yes
|
TR-453
|
12035-72-2 |
Nickel subsulfide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/53 3/53 6/53; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 3/53 6/53; ALVEOLAR/BRONCHIOLAR ADENOMA OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 6/53 11/53
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Rats |
F344/N |
Male |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 7/50 16/50 19/50 OR CARCINOMA 1/50 2/50 4/50 3/50 COMBINED 6/50 9/50 20/50 21/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 10/50 19/50 32/50 OR CARCINOMA 1/50 1/50 6/50 5/50 COMBINED 10/50 11/50 25/50 37/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/50 25/50 17/50 35/50 OR CARCINOMA 10/50 14/50 8/50 12/50 COMBINED 19/50 34/50 22/50 40/50
|
Neoplastic Lesions
|
Yes
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 3/50 2/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 3/50 5/50 3/50 COMBINED 3/50 6/50 6/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR ADENOMA 11/50 10/50 9/50 12/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 3/50 3/50 11/50 COMBINED 13/50 13/50 12/50 20/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 19/50 21/50 33/50 36/50 OR CARCINOMA 2/50 7/50 1/50 11/50 COMBINED 9/50 25/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/60 2/60 3/60 50/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 4/60 17/60 55/60 60/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(CECUM) CARCINOMA 0/60 1/60 4/60 3/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(CECUM) CARCINOMA 0/60 12/60 9/60 0/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/60 0/59 1/60 6/60
|
May Have Been Related
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60
|
Neoplastic Lesions
|
Yes
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 23/60 47/60 52/60 56/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
(SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
(SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60
|
Neoplastic Lesions
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 19/51 21/50 21/50 29/49 COMBINED 19/51 25/50 21/50 29/49
|
May Have Been Related
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA (STANDARD) 0/51 1/50 0/50 2/49 (EXTENDED) 4/51 12/50 1/50 5/49 COMBINED 4/51 13/50 1/50 6/49
|
May Have Been Related
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 1/50 1/50 8/49 COMBINED 1/50 1/50 1/50 10/49
|
Neoplastic Lesions
|
Yes
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ADEMONA 0/50 0/50 6/50 1/49 COMBINED 0/50 0/50 7/50 1/49
|
Neoplastic Lesions
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
FIBROMA 0/51 5/50 2/49 2/50 COMBINED 0/51 7/50 2/49 2/50
|
May Have Been Related
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
COMBINED 0/50 0/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-440
|
10028-15-6 |
Ozone |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
(LIFETIME STUDY) ALVEOLAR/BRONCHIOLAR ADENOMA 8/49 8/49 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 8/49 15/49 18/50 COMBINED 16/49 22/49 21/50
|
Neoplastic Lesions
|
No
|
TR-440
|
10028-15-6 |
Ozone |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
(2 YR. STUDY) ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 9/50 12/50 11/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 8/50 4/50 8/50 10/50 COMBINED 14/50 13/50 18/50 19/50
|
Neoplastic Lesions
|
Yes
|
TR-440
|
10028-15-6 |
Ozone |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
(2 YR. STUDY) ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 5/50 5/49 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 2/50 5/49 8/50 COMBINED 6/50 7/50 9/49 16/50
|
Neoplastic Lesions
|
Yes
|
TR-440
|
10028-15-6 |
Ozone |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
(LIFETIME STUDY) ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 3/49 11/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 5/49 2/50 COMBINED 6/50 8/49 12/50
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
benign pheochromocytoma (0/49, 3/50, 4/50, 6/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma (2/50, 6/50, 6/50, 8/50); adenoma or adenocarcinoma (2/50, 6/50, 9/50, 8/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (12/50, 14/50, 24/50, 34/50); hepatocellular carcinoma (7/50, 8/50, 12/50, 34/50); hepatoblastoma (0/50, 0/50, 1/50, 8/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma (8/50, 19/50, 16/50, 35/50); hepatoblastoma (1/50, 1/50, 1/50, 15/50)
|
Neoplastic Lesions
|
Yes
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Male |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma or carcinoma (0/50, 2/50, 0/50, 3/50)
|
May Have Been Related
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma (2/50, 8/50, 8/50, 14/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Male |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma (2/50, 5/49, 3/49, 12/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Uterus
|
Some Evidence |
Some Evidence |
adenocarcinoma (1/50, 1/50, 0/50, 5/50); stromal polyp (7/50, 9/50, 16/50, 12/50)
|
Neoplastic Lesions
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Rats |
Sprague Dawley |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Female |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Male |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
Yes
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-060
|
3546-10-9 |
Phenesterin |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-060
|
3546-10-9 |
Phenesterin |
Rats |
Sprague Dawley |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 12/50 8/50 13/50 18/50 18/50 14/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
Hematopoietic System: MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 2/50 9/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 2/50 1/50 0/50 2/50 31/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 0/50 3/50 38/50; ADENOMA 1/50 0/50 0/50 0/50 1/50 7/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 43/50; ADENOMA 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-508
|
23246-96-0 |
Riddelliine |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/50 COMBINED 2/50 13/50
|
Neoplastic Lesions
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-115
|
95-06-7 |
Sulfallate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-421
|
14807-96-6 |
Talc |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 13/48 14/47 18/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 10/49 COMBINED 13/48 14/47 23/49
|
Neoplastic Lesions
|
No
|
TR-421
|
14807-96-6 |
Talc |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 25/49 30/48 36/47 OR MALIGNANT PHEOCHROMOCYTOMA 3/49 3/48 7/47 COMBINED 26/49 32/48 37/47
|
Neoplastic Lesions
|
Yes
|
TR-421
|
14807-96-6 |
Talc |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 0/48 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/48 5/50 COMBINED 1/50 0/48 13/50
|
Neoplastic Lesions
|
Yes
|
TR-386
|
509-14-8 |
Tetranitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 19/50 41/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 11/50 45/50
|
Neoplastic Lesions
|
Yes
|
TR-386
|
509-14-8 |
Tetranitromethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 17/50 34/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 16/50 46/50
|
Neoplastic Lesions
|
Yes
|
TR-386
|
509-14-8 |
Tetranitromethane |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 6/50 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 19/50 50/50 COMBINED 0/50 22/50 50/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 12/50; MALIGNANT MIXED TUMORS 0/50 0/50 1/50; SARCOMA 0/50 0/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-386
|
509-14-8 |
Tetranitromethane |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 13/50 11/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/50 19/50, COMBINED 0/50 26/50 46/50; SQUAMOUS CELL CARCINOMA 1/50 1/50 19/50; SARCOMA 0/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/52 2/55 1/53 0/53 1/53 1/52 4/53 3/50
|
May Have Been Related
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
CHOLANGIOMA 0/53 0/55 0/53 0/53 0/53 1/51 1/53 0/50
|
May Have Been Related
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/55 1/53 0/53 5/53 6/51 22/53 2/50 OR ADENOMA 1/53 2/55 1/53 0/53 2/53 4/51 7/53 0/50 OR HEPATOCHOLANGIOMA 0/53 0/55 0/53 0/53 0/53 0/51 3/53 0/50
|
Neoplastic Lesions
|
Yes
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/55 0/53 0/53 1/53 11/51 35/51 0/50 OR SQUAMOUS CELL CARCINOMA 0/53 0/55 0/53 0/53 0/53 1/51 2/51 0/50
|
Neoplastic Lesions
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQUAMOUS CELL CARINOMA (ORAL MUCOSA) 0/53 1/55 1/53 1/53 2/53 2/53 7/53 2/50
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51
|
Neoplastic Lesions
|
Yes
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53
|
May Have Been Related
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/53 1/53 11/51 OR CHOLANGIOCARCINOMA 0/53 0/53 2/53 7/53 9/51
|
Neoplastic Lesions
|
Yes
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/53 2/53 20/53
|
Neoplastic Lesions
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/52 0/51 0/52 0/52 3/52 36/49 29/49 adenoma 0/52 1/51 1/52 4/52 12/52 24/49 1/49 hepatocholangioma 0/52 0/51 0/52 0/52 0/52 4/49 0/49
|
Neoplastic Lesions
|
Yes
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/51 0/52 0/52 0/52 0/52 20/50 0/50
|
Neoplastic Lesions
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
Adenoma 0/52 0/52 0/52 2/52 3/52 1/47 0/49 adenoma or carcinoma 0/50 0/52 0/52 2/52 3/52 2/47 0/49
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
Squamous cell carcinoma: 0/52 0/52 3/52 1/52 1/52 0/52 1/50
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Clear Evidence |
Carcinoma 2/52 2/52 1/52 3/52 4/52 3/52 11/50
|
Neoplastic Lesions
|
No
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/51 0/53 1/53 1/53 1/65 1/50 CHOLANGIOMA 0/53 0/51 0/53 1/53 0/53 0/65 0/50
|
May Have Been Related
|
No
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/51 5/53 19/53 28/53 12/65 19/50 ADENOMA 2/53 1/51 0/53 4/53 17/53 5/65 1/50 CARCINOMA 0/53 0/51 0/53 0/53 1/53 0/65 0/50
|
Neoplastic Lesions
|
Yes
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/51 0/53 20/53 49/53 41/66 12/50
|
Neoplastic Lesions
|
No
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 1/51 2/53 4/53 0/53 1/66 1/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50
|
Neoplastic Lesions
|
Yes
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Some Evidence |
Equivocal Evidence |
CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Some Evidence |
Some Evidence |
(ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50
|
Neoplastic Lesions
|
Yes
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA, ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 1/47 5/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 0/46 2/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/45 1/47 4/46
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 0/48 2/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46
|
Neoplastic Lesions
|
No
|
TR-507
|
1314-62-1 |
Vanadium pentoxide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/49 3/49 1/50 0/50 COMBINED ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 0/49 3/49 1/50 1/50
|
May Have Been Related
|
Yes
|
TR-507
|
1314-62-1 |
Vanadium pentoxide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 17/50 23/50 19/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 23/50 18/50 22/50 COMBINED 1/50 32/50 35/50 32/50
|
Neoplastic Lesions
|
Yes
|
TR-507
|
1314-62-1 |
Vanadium pentoxide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 13/50 16/50 26/50 15/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 12/50 29/50 30/50 35/50 COMBINED 22/50 42/50 43/50 43/50
|
Neoplastic Lesions
|
Yes
|
TR-507
|
1314-62-1 |
Vanadium pentoxide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 8/49 5/48 6/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 3/49 1/48 3/50 COMBINED 4/50 10/49 6/48 9/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Equivocal Evidence |
malignant mesothelioma 0/50 1/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/50 12/50 28/50 23/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Some Evidence |
mononuclear cell leukemia 10/50 11/50 13/50 25/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
(Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule adenoma 0/50 5/50 19/50 10/50 renal tubule carcinoma 0/50 7/50 31/50 18/50 renal tubule adenoma or carcinoma 0/50 11/50 37/50 27/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule carcinoma 0/50 2/50 1/49 1/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocholangiocarcionoma 1/50 2/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 25/50 21/50 36/50 29/50 hepatocellular carcinoma 8/50 14/50 12/50 17/50 hepatocellular adenoma or carcinoma 28/50 30/50 37/50 38/50 hepatocholangiocarcinoma 0/50 1/50 1/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
alveolar/bronchiolar carcinoma 1/50 2/50 7/50 5/49
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma 0/49 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma 3/50 4/50 6/48 11/50; carcinoma 0/50 6/50 2/48 2/50 adenoma or carcinoma 3/50 10/50 8/48 13/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Some Evidence |
Some Evidence |
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 11/50 13/50 16/50 22/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Some Evidence |
Some Evidence |
MALIGNANT MESOTHELIOMA (ALL ORGANS) 3/50 1/50 0/50 10/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 19/49 26/50 32/50 35/49 CARCINOMA 3/49 3/50 12/50 8/49 COMBINED 22/49 28/50 37/50 37/49
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/49 37/50 37/50 42/50 CARCINOMA 14/49 9/50 19/50 26/50 COMBINED 28/49 41/50 42/50 47/50 HEPATOBLASTOMA 0/49 4/50 6/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 3/50 3/50 6/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/50 5/50 5/50 7/50
|
May Have Been Related
|
Yes
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/49 5/50 17/50 12/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 12/49 12/50 22/50 17/50
|
Neoplastic Lesions
|